In particular, KDM family epigenetic inhibitors, such as P3FI‐90, have demonstrated potent anti-tumor activity in preclinical fusion-positive RMS models by deactivating PAX-FOXO1-mediated transcription [21]. The gene discussed is FOXO1; the disease is neoplasm.